Prescription Pricing for the People Act of 2025
Summary
The Prescription Pricing for the People Act of 2025 proposes a formal investigation into the business practices of pharmacy benefit managers (PBMs), the intermediaries that negotiate drug prices between insurance companies and manufacturers. The bill would direct the Federal Trade Commission (FTC) to examine whether these companies use their market power to engage in anti-competitive behavior, such as steering patients toward affiliated pharmacies or using complex rebate schemes that may drive up out-of-pocket costs for consumers.
If enacted, the FTC would be required to submit a report to Congress detailing its findings and providing recommendations to improve transparency and competition within the pharmaceutical supply chain. For everyday citizens, this legislation aims to determine if PBM practices are unfairly inflating the price of prescriptions at the pharmacy counter. By identifying potential market manipulations, the bill seeks to provide a foundation for future regulations that could lower drug prices and protect independent pharmacies from being sidelined by larger corporate entities.
